News

02 Jun 2025 1 min read

Lumos Diagnostics Reaches 50% Recruitment Milestone in FebriDx CLIA Waiver Clinical Study

Lumos Diagnostics has announced that the Company has now successfully achieved 61 bacterial positive patients, representing 50% of the target of 120 bacterial positive patient results required for the study...

Read article

COMPANY NEWS

27 May 2025 1 min read

Lumos Secures Sixth US Medicare Reimbursement for FebriDx®

Lumos has announced that it has received confirmation of Medicare reimbursement coverage for FebriDx from another Medicare Administrative Contractors (MACs), CGS Administrators...

Read article

COMPANY NEWS

19 May 2025 1 min read

Lumos Secures Fifth US Medicare Reimbursement for FebriDx®

Lumos has announced that it has received confirmation of Medicare reimbursement coverage for FebriDx from another...

Read article

COMPANY NEWS

14 May 2025 1 min read

Lumos Advances FebriDx® Sales with iMedical Purchase Order

Lumos has today announced that it has received and shipped a purchase order for FebriDx® from iMedical, Inc. for US$126,000, representing its largest single purchase order since the test's launch.

Read article

COMPANY NEWS

07 May 2025 1 min read

Q3 FY25 Investor Briefing

Lumos CEO and MD, Doug Ward, and CFO, Barrie Lambert, this week presented the Company's Q3 FY25 quarterly results...

Read article

COMPANY NEWS

07 May 2025 1 min read

MAY 2025 | ANALYST REPORT | More Medicare Reimbursement Coverage Secured for FebriDx

MST Access Senior Analyst Chris Kallos has released an updated report on Lumos Diagnostics, maintaining a valuation of A$0.10 per share and highlighting our significant progress...

Read article

COMPANY NEWS

30 Apr 2025 1 min read

Stockhead | Biocurious: Lumos shines a light on the post-pandemic rapid diagnosis sector

Lumos was recently featured in this insightful Stockhead article by business journalist Tim Boreham.

Read article

COMPANY NEWS

29 Apr 2025 1 min read

Quarterly Activity Statement & 4C | Period ending 31 March 2025

Lumos Diagnostics (ASX:LDX) has released its quarterly report for the period ending 31 March 2025....

Read article

COMPANY NEWS

23 Apr 2025 1 min read

Lumos secures additional US Medicare reimbursement coverage for FebriDx®

Lumos has announced that it has received confirmation of Medicare reimbursement coverage from two additional Medicare Administrative Contractors (MACs)...

Read article